Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628771 | 0.93 | SGK1 (0.67) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL13628738 | 0.91 | SGK1 (0.65) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL13628788 | 0.89 | SGK1 (0.71) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL13628790 | 0.88 | SGK1 (0.64) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL14066176 | 0.88 | SGK1 (0.73) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL13628696 | 0.86 | SGK1 (0.71) | SGK1LMNAALOX15ALDH1A1MEN1 | |
| SCHEMBL13628760 | 0.86 | SGK1 (0.61) | SGK1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13628711 | 0.85 | SGK1 (0.69) | SGK1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13628704 | 0.85 | SGK1 (0.69) | SGK1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13628791 | 0.85 | SGK1 (0.60) | SGK1LMNAALOX15ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | GRK4, SGK1, SGK2 | SGK1 2/4885LMNA 3414/4885ALOX15 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.